Genetics pioneer transforms global depression research through multi-omics discoveries

OXFORD, Oxfordshire, UK, 14 October 2025 -- In a compelling Genomic Press Interview published today in Genomic Psychiatry, Dr. Najaf Amin unveils transformative insights that fundamentally reshape international understanding of depression genetics. The Oxford University Associate Professor, ranked among the top scientists globally in genetics and the top women in science worldwide, shares ground breaking discoveries that promise to revolutionize how researchers across continents approach major depression. With over 350 peer-reviewed publications and an exceptional h-index of 125, Dr. Amin has positioned herself at the vanguard of molecular epidemiology, challenging long-held paradigms about depression pathogenesis through innovative multi-omics approaches that extend far beyond traditional genetic frameworks.

The interview, published as part of the Innovators & Ideas series, reveals how Dr. Amin transformed early career setbacks into scientific breakthroughs that now influence research laboratories from Europe to Asia. Her journey from Pakistan to becoming one of Oxford's leading molecular epidemiologists exemplifies the power of perseverance in advancing global medical knowledge. When traditional genome-wide association studies failed to produce significant results for depression, Dr. Amin pioneered alternative approaches that have since yielded extraordinary discoveries benefiting researchers and patients worldwide.

Revolutionary Discoveries Transform Global Treatment Paradigms

Dr. Amin's identification of the RCL1 gene mutation represents a watershed moment in depression research, opening entirely new avenues for understanding the disorder's biological mechanisms. This discovery connects primate-specific interlaminar astrocytes to depression pathogenesis, providing researchers worldwide with novel therapeutic targets previously unexplored. Her work challenges the conventional view of depression as primarily a neurotransmitter imbalance, instead revealing it as a systemic disease involving multiple bodily systems.

The scope of her contributions extends beyond single gene discoveries. Leading the most extensive published studies on epigenomics, metabolomics, and gut microbiome in major depression, Dr. Amin has identified 124 metabolites associated with the disorder, with 49 being entirely novel discoveries. These findings, published in prestigious journals including Nature Communications and JAMA Psychiatry, provide the international scientific community with crucial biomarkers that could revolutionize diagnosis and treatment approaches globally.

Systemic Disease Model Reshapes International Research Priorities

The interview reveals Dr. Amin's paradigm-shifting perspective on depression as fundamentally a systemic disease rather than purely a brain disorder. This conceptualization transforms how researchers worldwide approach the condition, encouraging investigation of immune system disturbances, hypothalamic-pituitary-adrenal axis dysfunction, oxidative stress, and metabolic perturbations. Her integrative approach, encompassing genomics, transcriptomics, proteomics, and single-cell analysis, provides unprecedented molecular insights that benefit laboratories across continents pursuing personalized medicine approaches.

Dr. Amin emphasizes the critical importance of understanding feedback loops among biological, psychological, and social factors in depression development and maintenance. This holistic view influences treatment strategies globally, moving beyond one-size-fits-all models toward personalized interventions tailored to individual biological markers, life histories, and environmental contexts. The implications extend to public health policies worldwide, as her research demonstrates why depression contributes to higher morbidity and mortality through its effects on multiple physiological systems.

Personal Journey Inspires Global Scientific Community

The interview provides intimate glimpses into the personal challenges that shaped Dr. Amin's scientific philosophy and resilience. Her transition from electronics enthusiast to world-renowned geneticist began with her own diagnosis of polycystic ovarian syndrome at age 19, sparking curiosity about genetic mechanisms that would define her career. The narrative of overcoming significant personal and professional obstacles, including navigating academia as a brown woman from a developing country, resonates with scientists worldwide facing similar barriers.

Dr. Amin candidly discusses critical moments that nearly derailed her career, including the departure of her supervisor early in her doctoral studies and initial project failures that left her without publications. Her mentor, Professor Cornelia van Duijn, played a pivotal role in transforming these setbacks into opportunities for growth. This relationship exemplifies the importance of mentorship in fostering scientific excellence across cultural and geographic boundaries.

Her advocacy for equality, diversity, and inclusion in scientific grant awards and promotions addresses systemic issues affecting researchers globally. Dr. Amin's observation that she must invest "at least twice the effort" of many European counterparts to achieve comparable outcomes highlights persistent inequities requiring international attention and reform.

Future Directions Promise Worldwide Impact

Looking forward, Dr. Amin outlines ambitious goals for experimentally verifying causal associations between genetic and environmental risk factors for depression. Her vision encompasses developing integrated models spanning the entire chain of causation from risk exposure to molecular perturbation to clinical outcomes. This comprehensive approach promises to benefit healthcare systems worldwide by enabling more effective prevention and intervention strategies.

The research particularly emphasizes understanding how discoveries apply across diverse populations, ensuring that advances in depression genetics benefit people regardless of geographic location or ethnic background. Dr. Amin's work on rare variants demonstrates that population-specific genetic factors require consideration in developing truly global solutions to depression treatment.

Her dedication to open-access publishing through Genomic Press ensures that these groundbreaking discoveries remain accessible to researchers worldwide, particularly those in resource-limited settings who might otherwise lack access to critical scientific literature. This commitment to scientific democratization amplifies the global impact of her research, enabling scientists everywhere to build upon her discoveries.

Dr. Najaf Amin's Genomic Press interview is part of a larger series called Innovators & Ideas that highlights the people behind today's most influential scientific breakthroughs. Each interview in the series offers a blend of cutting-edge research and personal reflections, providing readers with a comprehensive view of the scientists shaping the future. By combining a focus on professional achievements with personal insights, this interview style invites a richer narrative that both engages and educates readers. This format provides an ideal starting point for profiles that explore the scientist's impact on the field, while also touching on broader human themes. More information on the research leaders and rising stars featured in our Innovators & Ideas -- Genomic Press Interview series can be found on our publications website: https://genomicpress.kglmeridian.com/.

The Genomic Press Interview in Genomic Psychiatry titled "Najaf Amin: Rare coding genetic variation and downstream omics hold the key to understanding the pathogenesis of depression," is freely available via Open Access on 14 October 2025 in Genomic Psychiatry at the following hyperlink: https://doi.org/10.61373/gp025k.0089.

About Genomic Psychiatry: Genomic Psychiatry: Advancing Science from Genes to Society (ISSN: 2997-2388, online and 2997-254X, print) represents a paradigm shift in genetics journals by interweaving advances in genomics and genetics with progress in all other areas of contemporary psychiatry. Genomic Psychiatry publishes peer-reviewed medical research articles of the highest quality from any area within the continuum that goes from genes and molecules to neuroscience, clinical psychiatry, and public health.

Visit the Genomic Press Virtual Library: https://issues.genomicpress.com/bookcase/gtvov/

Our full website is at: https://genomicpress.kglmeridian.com/